Why are trials of Merck & Co's Keytruda+Moderna's personalised cancer vaccine mRNA-4157 generating particular interest amongst opinion leaders? What underpins experts' excitement about Iovance's tumour-infiltrating lymphocyte therapy Contego, and what factors do they say may limit its uptake? Do oncologists see a wider role in melanoma therapy for Immunocore/Medison Pharma's bispecific Kimmtrak? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to KOL Bulletins.
Table of Contents
Executive summary (7)
Treatment algorithm (1)
Research objectives (2)
Marketed therapies (35)
- Overview
- Immunotherapies (35)
- Opdivo/Yervoy (nivolumab/ipilimumab; Bristol Myers Squibb/Ono Pharmaceuticals) (14)
- Opdualag (nivolumab/relatlimab; Bristol Myers Squibb) (13)
- Keytruda (pembrolizumab; Merck & Co.) (8)
BRAF/MEK inhibitors (9)
- Overview (3)
- Marketed BRAF/MEK drugs (6)
- Tafinlar/Mekinist (dabrafenib/trametinib; Novartis) (1)
- Cotellic/Zelboraf (cobimetinib/vemurafenib; Roche) (1)
- Braftovi/Mektovi (encorafenib/binimetinib; Array BioPharma) (4)
Oncolytic viruses/immunostimulants (7)
- Overview (7)
- Imlygic (T-VEC/talimogene laherparepvec; Amgen) (6)
Pipeline therapies
Immune checkpoint inhibitors (12)
- Overview (12)
- Key insights summary (2)
- Libtayo ([cemiplimab)]/fianlimab; Regeneron) (1)
- Keytruda ([pembrolizumab]/vibostolimab; Merck & Co.) (9)
Recombinant immunostimulants (19)
- Overview (19)
- Key insights summary (3)
- mRNA-4157 (personalized cancer vaccine; Moderna) (1)
- Nidlegy (bifikafusp alfa + onfekafusp alfa; Philogen) (14)
Toll-like receptor 9 (TLR9) agonists (8)
Immunologic cytotoxicity/T lymphocyte stimulants (10)
- Overview (10)
- Key insights summary (2)
- Kimmtrak (tebentafusp; Immunocore/Medison Pharma) (7)
Histone deacetylase (HDAC) inhibitor (7)
- Overview (7)
- Key insights summary (2)
- Epidaza/Hiyasta (tucidinostat; HUYA Bioscience International) (5)
Tumour infiltrating lymphocyte (TIL) cell therapy (11)
- Key insights summary (11)
- Iovance's Contego TIL therapy excites KOLs as another potential option in the PD1-refractory setting (8)
Appendix (4)
- KOL details (4)
- KOLs from the USA (1)
- KOLs from Australia/Europe (2)